Sign up to save your podcasts
Or
Share ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.
View all episodes
By American Academy of Neurology
4.7
1919 ratings
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.
More shows like Neurology Today in 5
View all
Neurology® Podcast
293 Listeners
NEJM This Week
314 Listeners
Practical Neurology Podcast
48 Listeners
This Week in Cardiology
865 Listeners
JAMA Clinical Reviews
493 Listeners
JAMA Neurology Author Interviews
14 Listeners
JAMA Medical News
90 Listeners
BMJ Best Practice Podcast
25 Listeners
The Clinical Problem Solvers
514 Listeners
Neurology Minute
132 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
Neurology Exam Prep Podcast
183 Listeners
The Curious Clinicians
364 Listeners
The Lancet Neurology in conversation with
5 Listeners
Continuum Audio
79 Listeners